VITROLIFE AB UNSP/ADR - VTRLY STOCK NEWS

Vitrolife AB announces the departure of CFO Patrik Tolf due to personal reasons. Helena Wennerström has been appointed as acting CFO, bringing extensive experience from previous roles as CFO at ViaCon Group AB and EVP & CFO at Bulten AB. Wennerström will assume the position immediately, with Tolf supporting during a transition period. The company has initiated the recruitment process for a permanent CFO.

Vitrolife reported strong Q3 2024 performance with sales reaching SEK 867 million, showing a 7% increase in local currencies. The company saw regional growth of 9% in EMEA, 2% in Americas, and 9% in APAC. Business areas showed varied performance with Consumables up 13%, Technologies up 11%, while Genetics remained flat. The gross margin improved to 58.6% from 55.7%. EBITDA reached SEK 289 million with a 33.4% margin. For the first nine months, total sales were SEK 2,650 million, with a 4% increase in local currencies and improved EBITDA of SEK 888 million.

Vitrolife AB (publ) has announced a conference call to present its Q3 2024 interim report. The call is scheduled for Thursday, October 24, 2024, at 10:00 AM CET. Participants must register in advance to receive access details. The presentation will be conducted in English.

Key participants from Vitrolife include CEO Bronwyn Brophy O'Connor and CFO Patrik Tolf. The interim report press release will be issued at 8:00 AM CET on the same day, with presentation materials available on the company's website prior to the call.

A recorded version of the conference call will be accessible for seven days following the event. The company emphasizes that personal data will be processed in accordance with their privacy policy.

Vitrolife AB (publ) has announced the appointment of its election committee for the Annual General Meeting in 2025. The committee members are:

• Niels Jacobsen, appointed by William Demant Invest A/S
• Patrik Tigerschiöld, appointed by Bure Equity AB
• Patricia Hedelius, appointed by AMF Fonder & Pension
• Jón Sigurdsson, Chairman of the Board

The appointments follow the principles determined at the Annual General Meeting on April 25, 2024. The upcoming Annual General Meeting will be held on April 29, 2025 in Gothenburg. Shareholders wishing to propose items for consideration must submit their requests to the Board at least seven weeks before the meeting.

Vitrolife AB (publ) reported strong Q2 2024 results, with sales reaching SEK 941 million, a 4% increase in both local currencies and SEK. The company saw significant growth in its Technologies business area, up 40% in local currencies. Gross margin improved to 59.9%, while EBITDA increased to SEK 327 million with a margin of 34.7%. Net income rose to SEK 143 million, resulting in earnings per share of SEK 1.06.

Regionally, EMEA led growth at 11%, followed by Americas at 5%, while APAC declined by 5%. Vitrolife also made strategic acquisitions, including EMB's distribution activities and eFertility. The first half of 2024 showed overall positive trends, with improved financial metrics across the board.

Vitrolife Group will host a conference call on July 17, 2024, at 10:00 a.m. CET to discuss its Q2 2024 interim report. Participants include CEO Bronwyn Brophy O'Connor and CFO Patrik Tolf. The interim report will be released at 8:00 a.m. CET on the same day, with presentation materials available on the company's website beforehand. Registration for the call is required, and a recorded version will be accessible via an international phone number for seven days. This announcement was made on July 3, 2024, from Gothenburg, Sweden.

Vitrolife AB has finalized the acquisition of eFertility, a system and software company specializing in IVF clinic management. eFertility, known for its eWitness and eBase solutions, operates mainly in the Netherlands and is expanding across Europe. In 2023, eFertility achieved revenues of EUR 1.5 million, reflecting the growing demand for IVF witnessing systems. eFertility will be integrated into Vitrolife's Technologies business area, as announced by CEO Bronwyn Brophy O'Connor on May 22, 2024.

Vitrolife AB (publ) has acquired 100% of the shares in eFertility, a system and software company focused on transforming IVF clinic management. The acquisition is part of Vitrolife Group's strategy to standardize and digitalize IVF clinics globally. eFertility offers innovative solutions like eWitness and eBase, with revenues of EUR 1.5 million in 2023. The purchase price is EUR 9.6 million with a potential earn-out of EUR 8.4 million over three years. The acquisition is expected to close in mid-May 2024, financed by Vitrolife Group's cash.